Neuropace Inc
NASDAQ:NPCE
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
5.9
17.5
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one NPCE stock under the Base Case scenario is 9.6 USD. Compared to the current market price of 10.2 USD, Neuropace Inc is Overvalued by 6%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Neuropace Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for NPCE cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Neuropace Inc
Balance Sheet Decomposition
Neuropace Inc
Current Assets | 82.6m |
Cash & Short-Term Investments | 56.8m |
Receivables | 11.6m |
Other Current Assets | 14.2m |
Non-Current Assets | 13.7m |
PP&E | 13.3m |
Other Non-Current Assets | 425k |
Current Liabilities | 14.8m |
Accounts Payable | 2.2m |
Accrued Liabilities | 11.9m |
Other Current Liabilities | 749k |
Non-Current Liabilities | 71.7m |
Long-Term Debt | 59.3m |
Other Non-Current Liabilities | 12.4m |
Earnings Waterfall
Neuropace Inc
Revenue
|
76.5m
USD
|
Cost of Revenue
|
-20m
USD
|
Gross Profit
|
56.4m
USD
|
Operating Expenses
|
-79.5m
USD
|
Operating Income
|
-23.1m
USD
|
Other Expenses
|
-5m
USD
|
Net Income
|
-28.1m
USD
|
Free Cash Flow Analysis
Neuropace Inc
USD | |
Free Cash Flow | USD |
NPCE Profitability Score
Profitability Due Diligence
Neuropace Inc's profitability score is 28/100. The higher the profitability score, the more profitable the company is.
Score
Neuropace Inc's profitability score is 28/100. The higher the profitability score, the more profitable the company is.
NPCE Solvency Score
Solvency Due Diligence
Neuropace Inc's solvency score is 30/100. The higher the solvency score, the more solvent the company is.
Score
Neuropace Inc's solvency score is 30/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
NPCE Price Targets Summary
Neuropace Inc
According to Wall Street analysts, the average 1-year price target for NPCE is 15.47 USD with a low forecast of 8.08 USD and a high forecast of 21 USD.
Dividends
Current shareholder yield for NPCE is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
NPCE Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
NeuroPace, Inc. develops, manufactures and markets implantable devices for treating epilepsy and neurological disorders. The company is headquartered in Mountain View, California. The company went IPO on 2021-04-22. The firm is focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. The Company’s novel and differentiated RNS System is the brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source. The Company’s RNS System is a platform that delivers care for patients suffering from drug-resistant epilepsy and offers a personalized solution and outcomes to the patients suffering from other brain disorders. RNS System is a device that records brain activity data and clinicians to monitor patients. RNS System monitors the brain’s electrical activity, recognizes patient-specific abnormal patterns, and delivers treatment at the seizure source. The Company’s RNS System is engaged in treating other brain disorders including depression, impulse control disorders, memory disorders, and post-traumatic stress.
Contact
IPO
Employees
Officers
The intrinsic value of one NPCE stock under the Base Case scenario is 9.6 USD.
Compared to the current market price of 10.2 USD, Neuropace Inc is Overvalued by 6%.